Founded in 1990, Schrödinger operates through two primary business segments: Software and Drug Discovery. The Software segment, which generates the majority of its revenue, licenses advanced computational chemistry tools that integrate physics-based methods with machine learning to predict molecular properties and behaviors. The Drug Discovery segment focuses on advancing a portfolio of preclinical and clinical therapeutic programs, both internally and through strategic collaborations with major pharmaceutical companies such as Novartis and Bristol Myers Squibb. By enabling scientists to evaluate compounds in silico with high accuracy, the company's platform significantly accelerates the R&D process and reduces the reliance on costly physical lab experiments. Schrödinger is currently transitioning its software business toward cloud-based hosted contracts to support long-term recurring revenue.
